CA2659846A1 - Analogues de l'hormone parathyroidienne et leurs procedes d'utilisation - Google Patents

Analogues de l'hormone parathyroidienne et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2659846A1
CA2659846A1 CA002659846A CA2659846A CA2659846A1 CA 2659846 A1 CA2659846 A1 CA 2659846A1 CA 002659846 A CA002659846 A CA 002659846A CA 2659846 A CA2659846 A CA 2659846A CA 2659846 A1 CA2659846 A1 CA 2659846A1
Authority
CA
Canada
Prior art keywords
pth
bone
dose
ostabolin
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002659846A
Other languages
English (en)
Inventor
Paul Morley
Martin Stogniew
Brian Macdonald
Gene Scott Merutka
Nagesh R. Palepu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zelos Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/517,146 external-priority patent/US20070099831A1/en
Priority claimed from US11/650,918 external-priority patent/US20070270341A1/en
Application filed by Individual filed Critical Individual
Publication of CA2659846A1 publication Critical patent/CA2659846A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA002659846A 2006-07-31 2007-05-02 Analogues de l'hormone parathyroidienne et leurs procedes d'utilisation Abandoned CA2659846A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US83498006P 2006-07-31 2006-07-31
US60/834,980 2006-07-31
US83797206P 2006-08-15 2006-08-15
US60/837,972 2006-08-15
US11/517,146 2006-09-06
US11/517,146 US20070099831A1 (en) 2005-09-06 2006-09-06 Parathyroid hormone analogues and methods of use
US11/650,918 US20070270341A1 (en) 2005-09-06 2007-01-05 Parathyroid hormone analogues and methods of use
US11/650,918 2007-01-05
US90569307P 2007-03-07 2007-03-07
US60/905,693 2007-03-07
US92563907P 2007-04-20 2007-04-20
US60/925,639 2007-04-20
PCT/US2007/010720 WO2008016404A2 (fr) 2006-07-31 2007-05-02 Analogues de l'hormone parathyroïdienne et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA2659846A1 true CA2659846A1 (fr) 2008-02-07

Family

ID=56290957

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002659846A Abandoned CA2659846A1 (fr) 2006-07-31 2007-05-02 Analogues de l'hormone parathyroidienne et leurs procedes d'utilisation

Country Status (4)

Country Link
EP (1) EP2056862A2 (fr)
JP (1) JP2010501476A (fr)
CA (1) CA2659846A1 (fr)
WO (1) WO2008016404A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc eMIPを有効成分とする水溶性製剤
WO2014118705A1 (fr) * 2013-01-31 2014-08-07 Novartis Ag Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine
EP3685849A4 (fr) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation Composition pharmaceutique liquide contenant du tériparatide ayant une excellente stabilité
CN111032073A (zh) * 2017-09-22 2020-04-17 旭化成制药株式会社 药物动力学和/或安全性优异的含有特立帕肽的液态药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CA2126299C (fr) * 1994-06-20 2000-12-12 Gordon E. Willick Analogues de l'hormone parathyroidienne utilises pour le traitement de l'osteoporose
US6110892A (en) * 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
EE9900039A (et) * 1996-08-02 1999-08-16 National Research Council Of Canada Paratüreoidhormooni analoogid osteoporoosi raviks
US6316410B1 (en) * 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
ITMI20041440A1 (it) * 2004-07-19 2004-10-19 Abiogen Pharma Spa Peptidi analoghi del pth-1-11

Also Published As

Publication number Publication date
JP2010501476A (ja) 2010-01-21
EP2056862A2 (fr) 2009-05-13
WO2008016404A2 (fr) 2008-02-07
WO2008016404A3 (fr) 2009-01-15

Similar Documents

Publication Publication Date Title
US20070099831A1 (en) Parathyroid hormone analogues and methods of use
US7384912B2 (en) Treatment of bone disorders with skeletal anabolic drugs
US20070270341A1 (en) Parathyroid hormone analogues and methods of use
JP6275900B2 (ja) 骨粗鬆症治療剤ないし予防剤
US20080176787A1 (en) Parathyroid hormone analogues and methods of use
US20090010940A1 (en) Parathyroid Hormone Analogues and Methods of Use
CA2659846A1 (fr) Analogues de l'hormone parathyroidienne et leurs procedes d'utilisation
US20090042774A1 (en) Parathyroid hormone analogues and methods of use
MX2007003185A (es) Tratamiento de trastornos oseos con farmacos anabolicos esqueletales.

Legal Events

Date Code Title Description
FZDE Dead